Search

Displaying results 2051 - 2060 of 8517 in total
  1. Drug

    Metaxalone

    go.drugbank.com/drugs/DB00660
    ApprovedInvestigational

    Metaxalone is associated with few side effects and is available as a 800 mg scored tablet.

  2. Drug

    Prednisolone phosphate

    go.drugbank.com/drugs/DB14631
    ApprovedInvestigationalVet approved

    [A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144]

  3. Drug

    Lutetium Lu 177 dotatate

    go.drugbank.com/drugs/DB13985
    ApprovedInvestigational

    Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. … Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate.

  4. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombutasvir is also available as a fixed-dose combination product with [DB09297] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Ombutasvir first came on the market as a fixed-dose combination product with [DB09183], [DB09297], and [DB00503] as the FDA-approved product Viekira Pak.

    Synonyms: dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate
  5. Drug

    Pozanicline

    go.drugbank.com/drugs/DB05458
    Investigational

    In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes. … Neuronal nicotinic acetylcholine receptors (nAChRs) modulate the release of several important neurotransmitters, such as acetylcholine and dopamine.

  6. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). … Also known as the ileal bile acid transporter (IBAT), ASBT is primarily responsible for the enterohepatic recirculation of bile acids and ultimately for hepatic lipid and glucose metabolism [A32120].

  7. Drug

    Belinostat

    go.drugbank.com/drugs/DB05015
    ApprovedInvestigational

    It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.

  8. Drug

    Cedazuridine

    go.drugbank.com/drugs/DB15694
    ApprovedInvestigational

    [A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by … [A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells.

  9. Target

    Bcl2-associated agonist of cell death

    go.drugbank.com/bio_entities/BE0003421
    TargetHumans

    Successfully competes for the binding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the level of heterodimerization of these proteins with BAX.

    Synonyms: BAD
  10. Drug

    Tiagabine

    go.drugbank.com/drugs/DB00906
    Approved

    It is also used in the treatment for panic disorder as are a few other anticonvulsants. … Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.